Skip to content
Screener

Hemab Therapeutics Holdings, Inc. COAG Q2 2026 earnings

Reported May 21, 2026 · Before market open

EPS-$23.98Miss by $0.73
EPS estimate-$23.25

Next report

Aug 20, 2026 (In 1 week)
EPS estimate-$0.73

Financials

Q2 2026

Income statement

See full
Operating income-$26.1M-62.4%
Net income-$24.2M-97.8%
EPS (diluted)-$0.80+93.8%

Balance sheet

See full
Cash & equivalents$237.4M—
Total debt$1.0M—
Total equity$454.3M+421%
Total assets$467.8M—

Cash flow

See full
Operating cash flow-$22.6M-47.6%
CapEx$23.0K—
Free cash flow-$22.7M-47.8%

Valuation & ratios

Valuation

as of 08/10/26
See full
Market cap$2.32B+107%
Enterprise value$2.08B—

Returns & leverage

See full
Debt / equity0×—
Current ratio35.8×—

Versus estimates

Diluted EPS

Q2 2026-$23.98Miss by $0.73

FAQ

When did Hemab Therapeutics Holdings, Inc. report Q2 2026 earnings?
Hemab Therapeutics Holdings, Inc. (COAG) reported Q2 2026 earnings on May 21, 2026 before market open.
What were Hemab Therapeutics Holdings, Inc.'s Q2 2026 revenue and EPS?
Hemab Therapeutics Holdings, Inc. reported eps of $-23.98 for Q2 2026.
Did Hemab Therapeutics Holdings, Inc. beat estimates in Q2 2026?
EPS missed the consensus estimate of $-23.25 by $0.73.
Where can I find Hemab Therapeutics Holdings, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-233375) and the 10-Q periodic report (0001193125-26-344533) directly on SEC EDGAR. The filing index links above go to sec.gov.